title: [SICI-GISE position paper on drug-coated balloon use in the coronary district].
abstract: Drug-coated balloons are a new tool for the treatment of patients with coronary artery disease. The main feature of this technology is a rapid and homogeneous transfer of an antiproliferative drug (paclitaxel) to the vessel wall just at the time of balloon inflation, when neointimal proliferation, in response to angioplasty, is the highest. Moreover, drug-coated balloons share adjunctive advantages over stents: the absence of permanent scaffold and polymer, the respect of the original coronary anatomy, and limited inflammatory stimuli, thereby allowing for short-term dual antiplatelet therapy. At present, a variety of devices are available in the market, with limited scientific data for the vast majority of them. Thus, the Italian Society of Interventional Cardiology (SICI-GISE) decided to coordinate the efforts of a group of renowned experts in this field, in order to produce a position paper on the correct use of drug-coated balloons in all settings of coronary artery disease, giving a class of indication to each one, based on clinical evidence. This position paper represents a quick reference for operators, investigators and manufacturers to promote the understanding and the correct use of the drug-coated balloon technology in everyday clinical practice.
authors.forename: Bernardo
authors.initials: B
authors.lastname: Cortese
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Sgueglia
authors.forename: Sergio
authors.initials: S
authors.lastname: Berti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Biondi-Zoccai
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.forename: Ugo
authors.initials: U
authors.lastname: Limbruno
authors.forename: Francesco
authors.initials: F
authors.lastname: Bedogni
authors.forename: Alberto
authors.initials: A
authors.lastname: Cremonesi
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000191:economics / Q000295:instrumentation*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000628:therapy; D003327:Coronary Disease / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D054855:Drug-Eluting Stents; D004867:Equipment Design; D019317:Evidence-Based Medicine; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy; D058426:Neointima / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012042:Registries
chemical_list: D010975:Platelet Aggregation Inhibitors; D017239:Paclitaxel